Patient Savings Program
For eligible patients with prescription coverage that may require significant out-of-pocket (co-pay or co-insurance) expenses for their HIV medications, the Patient Savings Program (PSP) is a simple and easy way to reduce out-of-pocket costs for up to 1 year. Patients should refer to the Q&A below for Eligibility Rules and Regulations to determine whether they qualify. For more information, call 1-866-961-7169.
To enroll in the Janssen Therapeutics Patient Savings Program, print out the Instant Savings Card or complete the application form and call 1-866-961-7169 to activate your enrollment:
- Printable Instant Savings Card or
- Patient Savings Program Application Form
- For any questions regarding the Patient Savings Program please refer to the Patient Savings Program Q&A
- Reimbursement form for patients who use nonparticipating retail or mail order pharmacy
JanssenTherapeuticsLine is a convenient, toll-free hotline that provides support for patients seeking guidance about insurance coverage or financial assistance. Reach them by phone at 1-866-836-0114 or by fax at 1-866-836-0567, Monday through Friday from 8 am to 8 pm ET.
JanssenTherapeuticsLine offers helpful services including insurance benefit verification to help you understand your insurance coverage, assistance with prior authorizations, process and procedures relating to appeals or exceptions, alternate sources of payment, and additional information about patient assistance.
This information is provided for informational purposes only and represents no statement, promise, or guarantee by Janssen Therapeutics concerning levels of reimbursement, payment, or charge. We strongly suggest that you consult your payer organization about local reimbursement policies.
Important Safety Information
What is the most important information I should know about PREZISTA®?
- PREZISTA® can interact with other medicines and cause serious side effects. See “Who should not take PREZISTA®?”
- PREZISTA® may cause liver problems. Some people taking PREZISTA®, together with Norvir® (ritonavir), have developed liver problems which may be life-threatening. Your healthcare provider should do blood tests before and during your combination treatment with PREZISTA®. If you have chronic hepatitis B or C infection, your healthcare provider should check your blood tests more often because you have an increased chance of developing liver problems
- Tell your healthcare provider if you have any of these signs and symptoms of liver problems: dark (tea-colored) urine, yellowing of your skin or whites of your eyes, pale- colored stools (bowel movements), nausea, vomiting, pain or tenderness on your right side below your ribs, or loss of appetite
PREZISTA® (darunavir) is a prescription medicine. It is one treatment option in the class of HIV (human immunodeficiency virus) medicines known as protease inhibitors.
PREZISTA® is always taken with and at the same time as ritonavir (Norvir®), in combination with other HIV medicines for the treatment of HIV infection in adults. PREZISTA® should also be taken with food.
PREZISTA® does not cure HIV infection or AIDS and you may continue to experience illnesses associated with HIV-1 infection, including opportunistic infections. You should remain under the care of a doctor when using PREZISTA®.
Please read Important Safety Information below, and talk to your healthcare provider to learn if PREZISTA® is right for you.
- PREZISTA® may cause severe or life-threatening skin reactions or rash. Sometimes these skin reactions and skin rashes can become severe and require treatment in a hospital. You should call your healthcare provider immediately if you develop a rash. However, stop taking PREZISTA® and ritonavir combination treatment and call your healthcare provider immediately if you develop any skin changes with these symptoms: fever, tiredness, muscle or joint pain, blisters or skin lesions, mouth sores or ulcers, red or inflamed eyes, like “pink eye.” Rash occurred more often in patients taking PREZISTA® and raltegravir together than with either drug separately, but was generally mild
Who should not take PREZISTA®?
- Do not take PREZISTA® if you are taking the following medicines: alfuzosin (Uroxatral®), apixaban (Eliquis®), avanafil (Stendra®), boceprevir (Victrelis®), cisapride (Propulsid®), colchicine (Colcrys®, Col-Probenecid®) if you have liver or kidney problems, dabigatran etexilate (Pradaxa®) in specific renal impairment groups, dihydroergotamine (D.H.E.45®, Embolex®, Migranal®), dronedarone (Multaq®), ergotamine (Cafergot®, Ergomar®), everolimus (Zortress®, Afinitor®), indinavir (Crixivan®), lopinavir/ritonavir (Kaletra®), lovastatin (Mevacor®, Altoprev®, Advicor®), methylergonovine, oral midazolam (Versed®), pimozide (Orap®), ranolazine (Ranexa®), rifampin (Rifadin®, Rifater®, Rifamate®, Rimactane®), rifapentine (Priftin®), rivaroxaban (Xarelto®), saquinavir (Invirase®), salmeterol (Advair®, Serevent®), sildenafil (Revatio®) only when used to treat pulmonary arterial hypertension, simeprevir (Olysio®), simvastatin (Zocor®, Simcor®, Vytorin®), the herbal supplement or products containing St. John's Wort (Hypericum perforatum), telaprevir (Incivek®), triazolam (Halcion®), or voriconazole (VFend®)
- Before taking PREZISTA®, tell your healthcare provider if you are taking sildenafil (Viagra®, Revatio®), vardenafil (Levitra®, Staxyn®), tadalafil (Cialis®, Adcirca®), atorvastatin (Lipitor®), rosuvastatin (Crestor®), or pravastatin (Pravachol®)
- Tell your healthcare provider if you are taking estrogen-based contraceptives (birth control). PREZISTA® might reduce the effectiveness of estrogen-based contraceptives. You must take additional precautions for birth control, such as condoms
Serious problems can happen if you or your child takes any of these medicines with PREZISTA®.
This is not a complete list of medicines. Be sure to tell your healthcare provider about all the medicines you are taking or plan to take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Do not start any new medicines while you are taking PREZISTA® without first talking to your healthcare provider.
What should I tell my doctor before I take PREZISTA®?
- Before taking PREZISTA®, tell your healthcare provider if you have any medical conditions, including liver problems (including hepatitis B or C), allergy to sulfa medicines, diabetes, or hemophilia
- Tell your healthcare provider if you are pregnant or planning to become pregnant, or are breastfeeding
- The effects of PREZISTA® on pregnant women or their unborn babies are not known. You and your healthcare provider will need to decide if taking PREZISTA® is right for you
- Do not breastfeed. It is not known if PREZISTA® can be passed to your baby in your breast milk and whether it could harm your baby. Also, mothers with HIV should not breastfeed because HIV can be passed to your baby in the breast milk
What are the possible side effects of PREZISTA®?
- High blood sugar, diabetes or worsening of diabetes, and increased bleeding in people with hemophilia have been reported in patients taking protease inhibitor medicines, including PREZISTA®
- Changes in body fat have been seen in some patients taking HIV medicines, including PREZISTA®. The cause and long-term health effects of these conditions are not known at this time
- Changes in your immune system can happen when you start taking HIV medicines. Your immune system may get stronger and begin to fight infections that have been hidden
- The most common side effects related to taking PREZISTA® include diarrhea, nausea, rash, headache, stomach pain, and vomiting. This is not a complete list of all possible side effects. If you experience these or other side effects, talk to your healthcare provider. Do not stop taking PREZISTA® or any other medicines without first talking to your healthcare provider
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please refer to the ritonavir (Norvir®) Product Information (PI and PPI) for additional information on precautionary measures.
Please see accompanying full Product Information for more details.